Medivir AB (Medivir AB) Debt-to-Equity : 0.06 (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Medivir AB Debt-to-Equity?

Medivir AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.22 Mil. Medivir AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.10 Mil. Medivir AB's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $21.25 Mil. Medivir AB's debt to equity for the quarter that ended in Dec. 2023 was 0.06.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Medivir AB's Debt-to-Equity or its related term are showing as below:

MVRBF' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.07 Max: 0.24
Current: 0.06

During the past 13 years, the highest Debt-to-Equity Ratio of Medivir AB was 0.24. The lowest was 0.02. And the median was 0.07.

MVRBF's Debt-to-Equity is ranked better than
69.35% of 1070 companies
in the Biotechnology industry
Industry Median: 0.145 vs MVRBF: 0.06

Medivir AB Debt-to-Equity Historical Data

The historical data trend for Medivir AB's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medivir AB Debt-to-Equity Chart

Medivir AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.24

0.12

0.05

0.08

0.06

Medivir AB Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.08	-	-	-	0.06

Competitive Comparison of Medivir AB's Debt-to-Equity

For the Biotechnology subindustry, Medivir AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medivir AB's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medivir AB's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Medivir AB's Debt-to-Equity falls into.

Medivir AB Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Medivir AB's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.221	+	1.098)	/	21.245
	=	0.06

Medivir AB's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.221	+	1.098)	/	21.245
	=	0.06

Medivir AB (OTCPK:MVRBF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Medivir AB Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Medivir AB's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Medivir AB (Medivir AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medivir AB (OTCPK:MVRBF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

MVIR:Sweden MVR0:Germany

Address

Lunastigen 5, PO Box 1086, 2nd floor, Huddinge, SWE, 141 22

Website

https://www.medivir.com

Medivir AB develops drugs with a focus on cancers where there are medical needs. The company invests in indication areas where available treatment methods are limited or lacking and there are opportunities to offer significant improvements to patients. Medivir focuses on the development of MIV-818, a prodrug that has been designed to provide a targeted anti-tumor effect in the liver while minimizing any side effects. Birinapant, a SMAC mimetic, has been out-licensed for development in combination with IGM antibodies for the treatment of solid tumors.